• HOME
  • TEAM
  • NEWS
  • PORTFOLIO
  • INVESTORS
  • ESG / IMPACT
  • EVENT
  • CONTACT

What are you looking for?

Hadean Ventures
Hadean Ventures
Hadean Ventures
  • HOME
  • TEAM
  • NEWS
  • PORTFOLIO
  • INVESTORS
  • ESG / IMPACT
  • EVENT
  • CONTACT

    @hadeanventures

  • All
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • Current companies
  • Exited companies
  • News
  • Portfolio
  • Uncategorized
  • Attgeno announces approval of initiation of Phase 2 clinical trial of Supernitro in patients with acute pulmonary hypertension

    by @hadeanventures on June 2, 2022

    Attgeno announces approval of initiation of Phase 2 clinical trial of Supernitro...

    Continue Reading
  • Abliva decides on a SEK 200 million financing to fund Phase 2/3 study of KL1333 to interim analysis and bring in new global life science and institutional investors

    by @hadeanventures on June 1, 2022

    NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, HONG…

    Continue Reading
  • Gesynta Pharma’s drug candidate GS-248 granted Orphan Drug Designation by the FDA

    by @hadeanventures on April 27, 2022

    Gesynta Pharma’s drug candidate GS-248 granted Orphan Drug Designation in US by the FDA for…

    Continue Reading
  • Alex Therapeutics raises €3.5M in oversubscribed financing round

    by @hadeanventures on April 6, 2022

    Alex Therapeutics aspires to become the global go-to partner for pharma, and other life-science companies…

    Continue Reading
  • ALEX THERAPEUTICS

    by @hadeanventures on April 6, 2022

    Alex Therapeutics is a digital therapeutics (DTx) company based in Stockholm...

    Continue Reading
  • TARGED

    by @hadeanventures on February 28, 2022

    TargED Biopharmaceuticals (“TargED”), is a private biotechnology company...

    Continue Reading
  • TargED Biopharmaceuticals raises EUR 39 Million in Series A financing

    by @hadeanventures on February 22, 2022

    TargED Biopharmaceuticals raises EUR 39 Million in Series A financing

    Continue Reading
  • RIBBON BIOLABS

    by @hadeanventures on February 6, 2022

    Ribbon Biolabs are developing a new technology to synthesize DNA molecules...

    Continue Reading
  • Ribbon Biolabs raises EUR 18 million in its Series A financing

    by @hadeanventures on January 31, 2022

    Ribbon Biolabs Raises EUR 18 Million Series A Financing

    Continue Reading
  • EMERGENCE THERAPEUTICS

    by @hadeanventures on December 15, 2021

    Emergence Therapeutics is a European biopharmaceutical company...

    Continue Reading
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • →

Member of

Designed and developed by PageLook.no
Privacy Policy